MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis

Nature Communications

Volumn 6, Issue , 2015, Pages

  Pan, Wen ^a,b,c   Zhu, Shu ^c   Dai, Dai ^a,b   Liu, Zheng ^d   Li, Dan ^e   Li, Bin ^e   Gagliani, Nicola ^c   Zheng, Yunjiang ^c   Tang, Yuanjia ^a,b   Weirauch, Matthew T ^f   Chen, Xiaoting ^g   Zhu, Wei ^d   Wang, Yue ^d   Chen, Bo ^d   Qian, Youcun ^a   Chen, Yingxuan ^a   Fang, Jingyuan ^a   Herbst, Ronald ^d   Richman, Laura ^d   Jallal, Bahija ^d   Harley, John B ^f,h   Flavell, Richard A ^c   Yao, Yihong ^d   Shen, Nan ^a,b,f,i   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDIMMUNE   (United States)

^e INSTITUTE PASTEUR OF SHANGHAI   (China)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g University of Cincinnati   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CINTREDEKIN BESUDOTOX; GAMMA INTERFERON RECEPTOR 1; MICRORNA; MICRORNA 125A; STAT3 PROTEIN; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; MIRN125 MICRORNA, HUMAN; MIRN125 MICRORNA, MOUSE; RAG-1 PROTEIN;

DISEASE PREVALENCE; GENE EXPRESSION; HOMEOSTASIS; IMMUNE RESPONSE; PATHOGENICITY; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DOWN REGULATION; ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; C57BL MOUSE; CASE CONTROL STUDY; CELLULAR IMMUNITY; EXPERIMENTAL AUTOIMMUNE NEURITIS; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

MUS;

ANIMALS; CASE-CONTROL STUDIES; COLITIS; CROHN DISEASE; DOWN-REGULATION; HOMEODOMAIN PROTEINS; HOMEOSTASIS; HUMANS; IMMUNITY, CELLULAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICRORNAS; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; T-LYMPHOCYTES, REGULATORY;

EID: 84929193321     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8096     Document Type: Article

References (50)

1. Gregersen, P. K. & Olsson, L. M. Recent advances in the genetics of autoimmune disease. Annu. Rev. Immunol. 27, 363-391 (2009).
2. Baumgarth, N. & Bevins, C. L. Autoimmune disease: skin deep but complex. Nature 449, 551-553 (2007).
3. Nanda, S. Genetic variants suggest shared pathwaysto autoimmune disease. Nat. Rev. Rheumatol. 6, 675 (2010).
4. Littman, D. R. & Rudensky, A. Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140, 845-858 (2010).
5. Haas, J. et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J. Immunol. 179, 1322-1330 (2007).
6. Xavier, R. J. & Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427-434 (2007).
7. Brusko, T. & Atkinson, M. Treg in type 1 diabetes. Cell Biochem. Biophys. 48, 165-175 (2007).
8. Zheng, Y. et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445, 936-940 (2007).
9. Josefowicz, S. Z. & Rudensky, A. Control of regulatory T cell lineage commitment and maintenance. Immunity 30, 616-625 (2009).
10. Samstein, R. M. et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. Cell 151, 153-166 (2012).
11. Mendell, J. T. & Olson, E. N. MicroRNAs in stress signaling and human disease. Cell 148, 1172-1187.
12. van Rooij, E., Purcell, A. L. & Levin, A. A. Developing microRNA therapeutics. Circ. Res. 110, 496-507 (2012).
13. Jackson, A. L. & Levin, A. A. Developing microRNA therapeutics: approaching the unique complexities. Nucleic Acid Ther. 22, 213-225 (2012).
14. Jernas, M. et al. MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). BMC Immunol. 14, 32 (2013).
15. Cobb, B. S. et al. A role for Dicer in immune regulation. J. Exp. Med. 203, 2519-2527 (2006).
16. Lock, C. et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500-508 (2002).
17. Laurence, A. et al. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 37, 209-222 (2012).
18. Xu, L. L. et al. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity 33, 313-325 (2010).
19. Chang, J. H., Kim, Y. J., Han, S. H. & Kang, C. Y. IFN-gamma-STAT1 signal regulates the differentiation of inducible Treg: potential role for ROS-mediated apoptosis. Eur. J. Immunol. 39, 1241-1251 (2009).
20. Wei, J. et al. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc. Natl Acad. Sci. USA 104, 18169-18174 (2007).
21. Kota, J. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017 (2009).
22. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
23. Krutzfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689 (2005).
24. Hou, J. et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19, 232-243 (2011).
25. Weber, M. S. et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13, 935-943 (2007).
26. Youssef, S. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84 (2002).
27. Zhao, X. et al. MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum. 62, 3425-3435 (2010).
28. Hu, J. Y. et al. Increasing CCL5/CCR5 on CD4+ T cells in peripheral blood of oral lichen planus. Cytokine 62, 141-145 (2013).
29. Maldonado, R. A., Irvine, D. J., Schreiber, R. & Glimcher, L. H. A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature 431, 527-532 (2004).
30. O'Shea, J. J. & Paul, W. E. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327, 1098-1102 (2010).
31. O'Shea, J. J. & Paul, W. E. Mechanisms underlying lineage commitment and plasticity of helper CD4(+) T cells. Science 327, 1098-1102 (2010).
32. Vahedi, G. et al. STATs shape the active enhancer landscape of T cell populations. Cell 151, 981-993 (2012).
33. Nakayamada, S., Takahashi, H., Kanno, Y. & O'Shea, J. J. Helper T cell diversity and plasticity. Curr. Opin. Immunol. 24, 297-302 (2012).
34. Wan, Y. Y. & Flavell, R. A. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445, 766-770 (2007).
35. Dardalhon, V. et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat. Immunol. 9, 1347-1355 (2008).
36. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
37. Zhou, L. et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453, 236-240 (2008).
38. Ichiyama, K. et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J. Biol. Chem. 283, 17003-17008 (2008).
39. Rudra, D. et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat. Immunol. 13, 1010-1019 (2012).
40. Rudensky, A. Y. Regulatory T cells and Foxp3. Immunol. Rev. 241, 260-268 (2011).
41. Lu, L. F. et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142, 914-929 (2010).
42. Lu, L. F. et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30, 80-91 (2009).
43. Takahashi, H. et al. TGF-beta and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells. Nat. Immunol. 13, 587-595 (2012).
44. Duan, R., Pak, C. & Jin, P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum. Mol. Genet. 16, 1124-1131 (2007).
45. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577-1581 (2005).
46. Gebert, L. F. R. et al. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 42, 609-621 (2014).
47. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685-1694 (2013).
48. van Rooij, E. et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316, 575-579 (2007).
49. Zhu, S. et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J. Exp. Med. 207, 2647-2662.
50. Zhu, S. et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat. Med. 18, 1077-1086 (2012).